Ibex Investors’s Akcea Therapeutics Inc AKCA Stock Holding History

Ibex Investors’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,170	Closed	-$251K	–	276
2018 Q3	$251K	Buy	+7,170	New	+$217K	0.14%	52

Other funds holding AKCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ibex Investors's AKCA Position: Q4 2018 in Review

Ibex Investors sold out of Akcea Therapeutics Inc (AKCA) in Q4 2018, closing a stake of 7,170 shares — an estimated $251K sold.

Ibex Investors first reported a position in AKCA in Q3 2018 and held it in 1 quarter. The position peaked at $251K in Q3 2018. 62 funds tracked by Wall St. Rank hold AKCA as of Q4 2018.

Ibex Investors reported no remaining Akcea Therapeutics Inc position as of Q4 2018 after selling out during the quarter.
Ibex Investors sold 7,170 Akcea Therapeutics Inc shares in Q4 2018, an estimated $251K.
Ibex Investors first reported a position in Akcea Therapeutics Inc in Q3 2018 and held it in 1 quarter.
Ibex Investors's Akcea Therapeutics Inc position peaked at $251K in Q3 2018.
62 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2018.

Based on Ibex Investors's 13F filing for Q4 2018, filed 13 Feb 2019.